| Symbol | NYXH |
|---|---|
| Name | NYXOAH SA |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Medical/Dental Instruments |
| Address | RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT, 1435, Belgium |
| Telephone | +32 10459075 |
| Fax | — |
| — | |
| Website | https://www.nyxoah.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001857190 |
| Description | Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoahs solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Nyxoah SA <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001649553-26-000107 <b>Size:</b> 11 KB
Read moreNyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results
Read moreNyxoah Publie ses Résultats Financiers et Opérationnels du Deuxième Trimestre et du Premier Semestre 2026
Read moreNyxoah Publiera ses Résultats Financiers du Deuxième Trimestre 2026 le 5 août 2026
Read moreNyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026
Read moreNyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2026
Read moreNew Form SCHEDULE 13G/A - Nyxoah SA <b>Filed:</b> 2026-07-01 <b>AccNo:</b> 0001193125-26-291475 <b>Size:</b> 7 KB
Read more